Recordati Industria Chimica e Farmaceutica S.p.A. (OTCMKTS:RCDTF - Get Free Report)'s share price hit a new 52-week high during trading on Thursday . The company traded as high as $52.25 and last traded at $52.25, with a volume of 0 shares. The stock had previously closed at $52.25.
Wall Street Analysts Forecast Growth
Several research firms recently weighed in on RCDTF. Barclays raised shares of Recordati Industria Chimica e Farmaceutica to a "strong sell" rating in a research note on Tuesday, October 22nd. Royal Bank of Canada raised shares of Recordati Industria Chimica e Farmaceutica to a "hold" rating in a report on Monday, October 7th.
Check Out Our Latest Stock Report on RCDTF
Recordati Industria Chimica e Farmaceutica Stock Performance
The company has a current ratio of 1.36, a quick ratio of 0.95 and a debt-to-equity ratio of 0.73. The company has a fifty day moving average price of $52.25 and a two-hundred day moving average price of $51.89.
Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF - Get Free Report) last announced its earnings results on Tuesday, July 30th. The company reported $0.70 earnings per share for the quarter. The business had revenue of $622.00 million during the quarter. Recordati Industria Chimica e Farmaceutica had a net margin of 17.41% and a return on equity of 30.78%.
About Recordati Industria Chimica e Farmaceutica
(
Get Free Report)
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis.
Recommended Stories
Before you consider Recordati Industria Chimica e Farmaceutica, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recordati Industria Chimica e Farmaceutica wasn't on the list.
While Recordati Industria Chimica e Farmaceutica currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
